Brera Holdings PLC (BREA) Expands Commitment to Women’s Football and Multi-Club Ownership (‘MCO’) Model

Clene Inc.’s (CLNN) CNM-Au8(R) Significant Survival Benefits in New Analyses of Healey ALS Platform Trial Data

D-Wave Quantum Inc. (QBTS) Demonstrates Quantum Suprzemacy on a Real-World Problem

Adageis on Track to Exceed Q1 Growth Target, Expanding Healthcare AI Platform

Thumzup Media Corp. (TZUP) Boosts Shareholder Value with Share Buyback

MannKind Corporation (NASDAQ: MNKD)

November 3, 2008 at 4:06am

MannKind Corporation (NASDAQ: MNKD), a biopharmaceutical company, has focused their efforts on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. Technosphere® Insulin System, the company’s lead investigational product candidate, is currently in Phase 3 clinical trials in the U.S., Europe and Latin America. MannKind believes the Technosphere® Insulin System has the potential to revolutionize the way diabetes is treated. For further information, visit the Company’s web site at www.mannkindcorp.com.

Archives

Select A Month

Market Basics

New to the micro-cap markets?Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks and learn how to protect yourself.

Newsletter Publishers

Have an up and coming newsletter and want to be included in our coverage list? Looking to get more coverage and grow subscriptions? Register for coverage.

Public Companies

Are you a Small-Cap / Micro-Cap company looking for coverage? We'd love to hear from you. Fill out our quick contact form or send us a text.